Clinical Trials on Metastatic Castration-resistant Prostate Cancer (CRPCa) in South Africa

Total 155 results

Endocyte

Recruiting

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Australia, South Africa
Aragon Pharmaceuticals, Inc.

Completed

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom, Moldova, Republic of
Bayer

Terminated

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) (DaroAcT)

Prostatic Cancer, Castration-Resistant

United States
Nuvation Bio Inc.

Recruiting

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditions

United States, Australia
Exelixis

Completed

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1)

Pain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

Belgium, France, Italy, Canada, United States, Germany, United Kingdom, Australia, Netherlands, Spain, Austria, Ireland, Puerto Rico, Sweden
pharmaand GmbH
Foundation Medicine

Active, not recruiting

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

Metastatic Castration Resistant Prostate Cancer

United States, Canada, Spain, France, Australia, Ireland, Belgium, Denmark, United Kingdom, Germany, Israel, Italy
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

Metastatic Castration Resistant Prostate Cancer

United States, Spain, United Kingdom, France, Australia, Belgium, Denmark, Israel, Germany, Ireland, Canada, Italy
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma in the Soft Tissue | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States, Puerto Rico
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)

Prostate Cancer | Cancer of the Prostate | Nonmetastatic Castration-Resistant Prostate Cancer

Hong Kong, Canada, China, Germany, Spain, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Australia, Denmark, France, United States, Singapore, Poland, Malaysia, Turkey, Belgium, Argentina, Thailand, Slovakia, Brazil, Finland, Ita... and more
Suzhou Kintor Pharmaceutical Inc,

Completed

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
Costantine Albany
Hoosier Cancer Research Network; Achieve Life Sciences

Terminated

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Prostate Cancer | PSA | Metastatic Castrate-Resistant Prostate Cancer

United States, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

Castration-Resistant Prostatic Cancer

United States, China, Italy, Korea, Republic of, Taiwan, Australia, Sweden, Belgium, Canada, France, Hungary, Israel, Malaysia, Russian Federation, Portugal, Germany, Bulgaria, Spain, Netherlands, Turkey, United Kingdom, Ukraine, Po... and more
National Cancer Institute (NCI)

Completed

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostatic Adenocarcinoma | Castration Levels of Testosterone

United States, Switzerland, Mexico, Chile, Colombia
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
Sanofi
Genzyme, a Sanofi Company

Completed

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Prostate Cancer | Metastatic | Hormone Refractory

Brazil, South Africa, Sweden, Germany, Hungary
St Vincent's Hospital, Sydney

Recruiting

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO)

Metastatic Prostate Cancer

Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

Metastatic Castration-sensitive Prostate Cancer

United States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
NGM Biopharmaceuticals, Inc

Active, not recruiting

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Melanoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostate Cancer | Head Neck Squamous Cell Carcinoma

United States
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Bayer

Active, not recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Spain, Korea, Republic of, United Kingdom, Australia, Hong Kong, Singapore, Taiwan, Lithuania, Russian Federation, Turkey, France, Israel, Czechia, Italy, Germany, Finland, Austria, Poland, Hungary
Trans Tasman Radiation Oncology Group
Bayer; Peter MacCallum Cancer Centre, Australia

Recruiting

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE)

Advanced Prostate Carcinoma | Castrate Resistant Prostate Cancer | Cancer of Prostate | PSA

Australia, Singapore
Carolina Research Professionals, LLC
Bayer

Unknown

Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303) (Post-eRADicAte)

Prostate Cancer Metastatic

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (A-DREAM)

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
EMD Serono

Completed

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (PERSEUS)

Prostate Cancer Metastatic

United States, Australia, France, Poland, Russian Federation, Spain, Germany, Netherlands, Slovakia, Canada, South Africa, Belgium
Leiden University Medical Center
Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Anticancer...

Recruiting

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)

Prostatic Neoplasms, Castration-Resistant

Australia, Netherlands
Sanofi

Completed

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (TAXYNERGY)

Prostate Cancer Metastatic

United States, Canada
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Metastatic Hormone Refractory Prostate Cancer

United States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada
Genentech, Inc.

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Metastatic Prostate Cancer | Advanced Prostate Cancer

Korea, Republic of, United States, Australia
Dendreon

Completed

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Metastatic Prostate Cancer

United States
Peter MacCallum Cancer Centre, Australia
United States Department of Defense; Advanced Accelerator Applications; Australian... and other collaborators

Active, not recruiting

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)

Metastatic Hormone Naive Prostate Cancer

Australia
AstraZeneca

Completed

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (Capri)

Non-Metastatic Prostate Cancer

Czech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
Sanofi

Terminated

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide (PRIMCAB)

Prostate Cancer Metastatic

Canada, United States
Bavarian Nordic

Completed

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Prostate Cancer Metastatic

United States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
Amgen

Completed

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Carcinoma | Cancer | Prostate Cancer | Tumors | Castrate-Resistant Prostate Cancer

United States, Canada, Poland, Hungary, Finland, Mexico
Eli Lilly and Company
Sarah Cannon Development Innovations

Completed

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Prostate Cancer Metastatic

United States
US Oncology Research
Pfizer

Completed

Phase II Sunitinib Prog Met AIPC

Metastatic Prostate Cancer

United States
Christopher Sweeney, MBBS
Sanofi; Hoosier Cancer Research Network; Walther Cancer Institute

Terminated

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Metastatic Prostate Cancer

United States, Canada
Australian and New Zealand Urogenital and Prostate...
Endocyte; Movember Foundation; Australian Nuclear Science and Technology Organisation... and other collaborators

Completed

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (TheraP)

Metastatic Cancer | Cancer of the Prostate

Australia
Movember Foundation
King's College London; Centre hospitalier de l'Université de Montréal (CHUM); University of California, San Francisco and other collaborators

Active, not recruiting

INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4) (INTERVAL)

Metastatic Prostate Cancer

United States, Australia, Netherlands, Canada, United Kingdom, Germany, Ireland
Pfizer

Recruiting

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Small Cell Lung Cancer (SCLC) | Follicular Lymphoma (FL) | Castration Resistant Prostate Cancer (CRPC)

United States, Spain, Korea, Republic of, Poland, China, Bulgaria, Russian Federation, Japan
Telix Pharmaceuticals (Innovations) Pty Ltd

Recruiting

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only (PROSTACT)

Metastatic Prostate Cancer

Australia, New Zealand
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Astellas Pharma US, Inc.; Medivation, Inc.; Biologics...

Active, not recruiting

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States, Canada, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)

Prostatic Neoplasms, Castration-Resistant

United States, Korea, Republic of, Belgium, United Kingdom, Canada, China, Denmark, France, Greece, Poland, Spain, Italy, Czechia, Japan, Switzerland, Australia, Germany, Austria, Hungary, Russian Federation, Taiwan
VA Office of Research and Development

Recruiting

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers (VA-BAT)

Metastatic Prostate Cancer

United States
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States

Clinical Trials on Metastatic Castration-resistant Prostate Cancer (CRPCa) in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations